Clinical trial NCT02881892 - References

Chronic Kidney Disease — Iplasma IL6, Procalcitonin and VEGF and Dialysate Level in CAPD Patients

Citation(s)

•   Alscher DM, Mettang T
  Procalcitonin in peritoneal dialysis--a useful marker of inflammation? Perit Dial Int. 2005 Sep-Oct;25(5):441-4.
•   Guz G, Colak B, Hizel K, Reis KA, Erten Y, Bali M, Sindel S
  Procalcitonin and conventional markers of inflammation in peritoneal dialysis patients and peritonitis. Perit Dial Int. 2006 Mar-Apr;26(2):240-8.
•   Herget-Rosenthal S, Klein T, Marggraf G, Hirsch T, Jakob HG, Philipp T, Kribben A
  Modulation and source of procalcitonin in reduced renal function and renal replacement therapy. Scand J Immunol. 2005 Feb;61(2):180-6.
•   Oh KH, Jung JY, Yoon MO, Song A, Lee H, Ro H, Hwang YH, Kim DK, Margetts P, Ahn C
  Intra-peritoneal interleukin-6 system is a potent determinant of the baseline peritoneal solute transport in incident peritoneal dialysis patients. Nephrol Dial Transplant. 2010 May;25(5):1639-46. doi: 10.1093/ndt/gfp670. Epub 2010 Jan 8.
•   Pecoits-Filho R, Araújo MR, Lindholm B, Stenvinkel P, Abensur H, Romão JE Jr, Marcondes M, De Oliveira AH, Noronha IL
  Plasma and dialysate IL-6 and VEGF concentrations are associated with high peritoneal solute transport rate. Nephrol Dial Transplant. 20

Interleukin-6, Procalcitonin and Vascular Endothelial Growth Factor in Plasma and Dialysate Correlate With Peritoneal Solute Transport and Dialysis Adequacy in CAPD Patients

Details for clinical trial NCT02881892